Higher short-term virologic efficacy of three-class versus two-class highly active antiretroviral salvage therapy in HIV-infected patients

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 19, Issue 5, 2000, Pages 380-384

  Baldanti, F ^a   Paolucci, S ^a   Maserati, R ^b   Maggiolo, F ^c   Pan, A ^d   Castelli, F ^e   Gulminetti, R ^a   Comolli, G ^a   Chiesa, A ^a   Gerna, G ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d CREMONA HOSPITAL   (Italy)

^e UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; NELFINAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; VIRUS LOAD;

EID: 0034087765     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050499     Document Type: Article

References (15)

1. 1. Lorenzi P, Opravil M, Hirschel B, Chave JP, Furrer HJ, Sax H, Perneger TV, Perrin L, Kaiser L, Yerly S, and the Swiss HIV Cohort Study: Impact of drug resistance mutations on virologic response to salvage therapy. AIDS (1999) 13:F17-F2I
2. 2. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vézinet F, Clotet B, Demeter LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C, Mellors JW, Vella S, Richman DD: Antiretroviral drug resistance testing in adults with HIV infection. JAMA (1998) 279: 1984-1991
3. 3. Lawrence J, Schapiro J, Winters M, Montoya J, Zolopa A, Pesano R, Efron B, Winslow D, Merigan TC: Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. Journal of Infectious Diseases (1999) 179: 1356-1364
4. 4. Boden D, Markowitz M: Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrobial Agents and Chemotherapy (1998) 42:2775-2783
5. 5. Moyle GJ: Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: the potential to use resistance data to guide clinical decisions. Journal of Antimicrobial Chemotherapy (1997) 40:765-777
6. 6. Lacey SF, Larder BA: Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrobial Agents and Chemotherapy (1994) 38:1428-1432
7. 7. Stuyver L, Wyseur A, Rombout A, Louwagie J, Scarcez T, Verhofstede C, Rimland D, Schinazi RF, Rossau R: Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrobial Agents and Chemotherapy (1997) 41:284-291
8. 8. Winters MA, Shapiro JM, Lawrence J, Merigan TC: Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. Journal of Virology (1998) 72:5303-5306
9. 9. Ho D, Webber S: Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrobial Agents and Chemotherapy (1996) 40:292-297
10. 10. Perry CM, Benfield P: Nelfinavir. Drugs (1997) 54:81-87
11. 11. Patick AK, Durant M, Cao Y, Shugarts D, Keller MR, Mazabel E, Knowels M, Chapman S, Kuritzkes DR, Markowitz M: Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrobial Agents and Chemotherapy (1998) 42:2637-2644
12. 12. Izopel J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J, Massip P: Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine. Journal of Medical Virology (1999) 59:507-511
13. 13. Arts EJ, Quinones-Mateu ME, Albright GL, Marois JP, Hough C, Gu Z, Wainberg MA: 3′-azido-3′-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants. Journal of Virology (1998) 72:4858-4865
14. 14. Eberle J, Bechowsky B, Rose D, Hauser U, Von Der Helm K, Gurtler L, Nitschko H: Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Research and Human Retroviruses (1995) 11:671-676
15. 15. Edelstein RE, Nickerson DA, Tobe VO, Manns-Arcuino LA, Frenkel LM: Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine and lamivudine. Journal of Clinical Microbiology (1998) 36:569-572